PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ATRA vs. AUTL
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ATRA and AUTL is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

ATRA vs. AUTL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Atara Biotherapeutics, Inc. (ATRA) and Autolus Therapeutics plc (AUTL). The values are adjusted to include any dividend payments, if applicable.

-100.00%-95.00%-90.00%-85.00%-80.00%SeptemberOctoberNovemberDecember2025February
-99.19%
-91.84%
ATRA
AUTL

Key characteristics

Sharpe Ratio

ATRA:

-0.47

AUTL:

-1.07

Sortino Ratio

ATRA:

-0.13

AUTL:

-1.99

Omega Ratio

ATRA:

0.98

AUTL:

0.78

Calmar Ratio

ATRA:

-0.56

AUTL:

-0.73

Martin Ratio

ATRA:

-1.19

AUTL:

-1.46

Ulcer Index

ATRA:

46.63%

AUTL:

47.99%

Daily Std Dev

ATRA:

117.38%

AUTL:

65.64%

Max Drawdown

ATRA:

-99.64%

AUTL:

-96.58%

Current Drawdown

ATRA:

-99.46%

AUTL:

-95.75%

Fundamentals

Market Cap

ATRA:

$50.23M

AUTL:

$542.89M

EPS

ATRA:

-$24.94

AUTL:

-$1.28

Total Revenue (TTM)

ATRA:

$96.19M

AUTL:

$10.09M

Gross Profit (TTM)

ATRA:

$81.97M

AUTL:

$6.17M

EBITDA (TTM)

ATRA:

-$65.15M

AUTL:

-$147.22M

Returns By Period

In the year-to-date period, ATRA achieves a -35.46% return, which is significantly lower than AUTL's -13.19% return.


ATRA

YTD

-35.46%

1M

-34.73%

6M

22.54%

1Y

-55.46%

5Y*

-52.62%

10Y*

-33.07%

AUTL

YTD

-13.19%

1M

-12.45%

6M

-45.60%

1Y

-71.19%

5Y*

-28.90%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ATRA vs. AUTL — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATRA
The Risk-Adjusted Performance Rank of ATRA is 2121
Overall Rank
The Sharpe Ratio Rank of ATRA is 2121
Sharpe Ratio Rank
The Sortino Ratio Rank of ATRA is 2828
Sortino Ratio Rank
The Omega Ratio Rank of ATRA is 2929
Omega Ratio Rank
The Calmar Ratio Rank of ATRA is 1414
Calmar Ratio Rank
The Martin Ratio Rank of ATRA is 1515
Martin Ratio Rank

AUTL
The Risk-Adjusted Performance Rank of AUTL is 44
Overall Rank
The Sharpe Ratio Rank of AUTL is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of AUTL is 22
Sortino Ratio Rank
The Omega Ratio Rank of AUTL is 44
Omega Ratio Rank
The Calmar Ratio Rank of AUTL is 77
Calmar Ratio Rank
The Martin Ratio Rank of AUTL is 66
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ATRA vs. AUTL - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Atara Biotherapeutics, Inc. (ATRA) and Autolus Therapeutics plc (AUTL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ATRA, currently valued at -0.47, compared to the broader market-2.000.002.004.00-0.47-1.07
The chart of Sortino ratio for ATRA, currently valued at -0.13, compared to the broader market-6.00-4.00-2.000.002.004.006.00-0.13-1.99
The chart of Omega ratio for ATRA, currently valued at 0.98, compared to the broader market0.501.001.502.000.980.78
The chart of Calmar ratio for ATRA, currently valued at -0.56, compared to the broader market0.002.004.006.00-0.56-0.73
The chart of Martin ratio for ATRA, currently valued at -1.19, compared to the broader market-10.000.0010.0020.0030.00-1.19-1.46
ATRA
AUTL

The current ATRA Sharpe Ratio is -0.47, which is higher than the AUTL Sharpe Ratio of -1.07. The chart below compares the historical Sharpe Ratios of ATRA and AUTL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00SeptemberOctoberNovemberDecember2025February
-0.47
-1.07
ATRA
AUTL

Dividends

ATRA vs. AUTL - Dividend Comparison

Neither ATRA nor AUTL has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ATRA vs. AUTL - Drawdown Comparison

The maximum ATRA drawdown since its inception was -99.64%, roughly equal to the maximum AUTL drawdown of -96.58%. Use the drawdown chart below to compare losses from any high point for ATRA and AUTL. For additional features, visit the drawdowns tool.


-100.00%-98.00%-96.00%-94.00%-92.00%-90.00%SeptemberOctoberNovemberDecember2025February
-99.21%
-95.75%
ATRA
AUTL

Volatility

ATRA vs. AUTL - Volatility Comparison

Atara Biotherapeutics, Inc. (ATRA) has a higher volatility of 66.39% compared to Autolus Therapeutics plc (AUTL) at 15.22%. This indicates that ATRA's price experiences larger fluctuations and is considered to be riskier than AUTL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


20.00%30.00%40.00%50.00%60.00%70.00%SeptemberOctoberNovemberDecember2025February
66.39%
15.22%
ATRA
AUTL

Financials

ATRA vs. AUTL - Financials Comparison

This section allows you to compare key financial metrics between Atara Biotherapeutics, Inc. and Autolus Therapeutics plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab